Treating NSCLC With Nintedanib

Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120).

Clinical Pearls:

  • Nintedanib was studied in combination with docetaxel in a phase III randomized study of NSCLC
  • This study showed an improvement in progression-free survival
  • In a second trial, in combination with pemetrexed, nintedanib showed no benefit to progression-free survival